Wooree Bio KRX:082850KOSDAQ
우리바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, Wooree Bio reported revenue of ₩316bn, up 37.0% year on year, and an operating loss of ₩2.4bn. Wooree Bio (우리바이오) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Revenue +30% Screener
Wooree Bio quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩316bn | +37.0% | −₩2.4bn margin −0.8% | −₩2.8bn |
| Q1 2026 | ₩269bn | -9.8% | −₩4.3bn margin −1.6% | ₩351m |
| Q4 2025 derived | ₩251bn | -13.5% | ₩154m margin 0.1% | −₩2.1bn |
| Q3 2025 | ₩264bn | -24.2% | ₩2.4bn margin 0.9% | ₩2.7bn |
| Q2 2025 | ₩231bn | -24.7% | −₩2.3bn margin −1.0% | −₩10.2bn |
| Q1 2025 | ₩298bn | +2.1% | ₩775m margin 0.3% | −₩528m |
| Q4 2024 derived | ₩290bn | -8.4% | −₩4.0bn margin −1.4% | −₩5.5bn |
| Q3 2024 | ₩348bn | -10.4% | ₩6.2bn margin 1.8% | ₩1.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Wooree Bio top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Wooree Bio news Korean headlines
No articles yet.